Kimi E. Iguchi
Net Worth

Last updated:

What is Kimi E. Iguchi net worth?

The estimated net worth of Ms. Kimi E. Iguchi is at least $11,446,513 as of 2 Jan 2024. She owns shares worth $12,279 as insider, has earned $4,336,374 from insider trading and has received compensation worth at least $7,097,860 in Sage Therapeutics, Inc..

What is the salary of Kimi E. Iguchi?

Ms. Kimi E. Iguchi salary is $645,260 per year as Chief Financial Officer & Treasurer in Sage Therapeutics, Inc..

How old is Kimi E. Iguchi?

Ms. Kimi E. Iguchi is 63 years old, born in 1962.

What stocks does Kimi E. Iguchi currently own?

As insider, Ms. Kimi E. Iguchi owns shares in one company:

Company Title Shares Price per share Total value
Sage Therapeutics, Inc. (SAGE) Chief Financial Officer & Treasurer 1,413 $8.69 $12,279

What does Sage Therapeutics, Inc. do?

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE logo
SAGE
Sage Therapeutics, Inc.
$8.69

Kimi E. Iguchi insider trading

Sage Therapeutics, Inc.

Ms. Kimi E. Iguchi has made 17 insider trades between 2014-2024, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 25,563 units of SAGE stock on 1 Mar 2019. As of 2 Jan 2024 she still owns at least 1,413 units of SAGE stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 1,642 $1.36 $2,233
Option
Common Stock 1,642 $1.36 $2,233
Option
Stock Option (Right to Buy) 3,000 $1.36 $4,080
Option
Common Stock 3,000 $1.36 $4,080
Option
Common Stock 250 $1.36 $340
Option
Stock Option (Right to Buy) 250 $1.36 $340
Option
Common Stock 750 $1.36 $1,020
Option
Stock Option (Right to Buy) 750 $1.36 $1,020
Option
Common Stock 1,600 $1.36 $2,176
Option
Stock Option (Right to Buy) 1,600 $1.36 $2,176
Option
Common Stock 1,800 $1.36 $2,448
Option
Stock Option (Right to Buy) 1,800 $1.36 $2,448
Option
Stock Option (Right to Buy) 4,500 $1.36 $6,120
Option
Common Stock 4,500 $1.36 $6,120
Option
Stock Option (Right to Buy) 495 $1.36 $673
Option
Common Stock 1,000 $1.36 $1,360
Option
Stock Option (Right to Buy) 505 $1.36 $687
Option
Stock Option (Right to Buy) 2,500 $1.36 $3,400
Option
Common Stock 2,500 $1.36 $3,400
Option
Stock Option (Right to Buy) 2,000 $1.36 $2,720
Option
Common Stock 2,000 $1.36 $2,720
Option
Common Stock 3,000 $1.36 $4,080
Option
Stock Option (Right to Buy) 3,000 $1.36 $4,080
Option
Stock Option (Right to Buy) 1,500 $0.68 $1,020
Option
Stock Option (Right to Buy) 1,500 N/A N/A
Option
Common Stock 1,500 N/A N/A
Option
Stock Option (Right to Buy) 1,750 N/A N/A
Option
Common Stock 1,750 N/A N/A
Option
Common Stock 4,000 N/A N/A
Option
Stock Option (Right to Buy) 4,000 N/A N/A
Option
Common Stock 500 N/A N/A
Option
Stock Option (Right to Buy) 500 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Stock Option (Right to Buy) 15,000 N/A N/A
Option
Common Stock 2,000 N/A N/A
Option
Stock Option (Right to Buy) 2,000 N/A N/A
Option
Stock Option (Right to Buy) 4,000 N/A N/A
Option
Common Stock 4,000 N/A N/A
Option
Common Stock 4,723 N/A N/A
Option
Stock Option (Right to Buy) 4,723 N/A N/A
Sale
Common Stock 25,563 N/A N/A
Option
Common Stock 800 N/A N/A
Option
Stock Option (Right to Buy) 800 N/A N/A
Sale
Common Stock 12,782 $144.71 $1,849,734
Sale
Common Stock 12,782 N/A N/A
Sale
Common Stock 11,018 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 5,000 $144.32 $721,580
Sale
Common Stock 12,135 $145.45 $1,765,060
Sale
Common Stock 12,135 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 4,000 N/A N/A
Sale
Common Stock 1,500 N/A N/A
Sale
Common Stock 2,500 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Stock Option (Right to Buy) 4,000 N/A N/A
Option
Common Stock 4,000 N/A N/A
Purchase
Common Stock 176 N/A N/A
Sale
Common Stock 3,000 N/A N/A
Sale
Common Stock 4,000 N/A N/A
Sale
Common Stock 4,000 N/A N/A
Sale
Common Stock 2,500 N/A N/A
Purchase
Common Stock 6,000 N/A N/A

Sage Therapeutics key executives

Sage Therapeutics, Inc. executives and other stock owners filed with the SEC: